PRIMARY INTRACEREBRAL MALIGNANT-LYMPHOMA - A CLINICOPATHOLOGICAL STUDY OF 89 PATIENTS

被引:73
作者
TOMLINSON, FH
KURTIN, PJ
SUMAN, VJ
SCHEITHAUER, BW
OFALLON, JR
KELLY, PJ
JACK, CR
ONEILL, BP
机构
[1] MAYO CLIN & MAYO FDN,DEPT NEUROL,ROCHESTER,MN 55905
[2] MAYO CLIN & MAYO FDN,DEPT NEUROL SURG,ROCHESTER,MN 55905
[3] MAYO CLIN & MAYO FDN,DEPT LAB MED & PATHOL,ROCHESTER,MN 55905
[4] MAYO CLIN & MAYO FDN,DEPT HLTH SCI RES,BIOSTAT SECT,ROCHESTER,MN 55905
[5] MAYO CLIN & MAYO FDN,DEPT DIAGNOST RADIOL,ROCHESTER,MN 55905
[6] MAYO CLIN & MAYO FDN,CTR COMPREHENS CANC,CANC STAT UNIT,ROCHESTER,MN 55905
关键词
PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; BRAIN NEOPLASM; NON-HODGKINS LYMPHOMA;
D O I
10.3171/jns.1995.82.4.0558
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The authors report on a clinicopathological study of 89 surgical patients with histologically proven primary parenchymal brain lymphoma, all diagnosed between January 1975 and December 1990. The cohort included 60 men and 29 women whose median age at diagnosis was 60 years (range 14 to 84 years). The duration of symptoms was less than 8 weeks in 48% of the patients. Symptom groups included focal neurological deficit (73%), neuropsychiatric symptoms (28%), seizures (9%), and increased intracranial pressure (3%). A total of 132 tumors were seen in 89 patients: the most common sites were frontal (32 patients), temporoparietal (31 patients), and basal ganglia (17 patients); multiple lesions were reported in 23 patients. No patient had antecedent of human immunodeficiency virus positivity or acquired immunodeficiency syndrome. A family history of cancer was present in 33% of the patients, three-quarters of whom were first-degree relatives. Histological subtypes (National Cancer Institute Working Formulation) included 64 large cell (72%) and 13 immunoblastic (15%) tumors. Phenotype was determined in 66 patients: 63 were B-cell type and three were T-cell type. Surgical resection was performed in 47% of the cases, with the remainder undergoing biopsy only. All but six patients received radiation therapy. Thirty-one patients received chemotherapy, whereas 46 patients did not; data on the remaining 12 patients were unavailable. The end point of the study was death from any cause. At the time of last contact, 69 of the patients (78%) had died; the median survival time for this study group was 20.9 months. On univariate analysis, prognostic factors significantly associated with survival included age at diagnosis, family history of cancer, and focal neurological deficit. Multivariate analysis revealed four unfavorable prognostic factors: age greater than or equal to 60 years, history of cancer in first-degree relatives, focal deficit, and ependymal contact. After adjustment for these variables, clinical syndrome, size and number of lesions, extent of surgery, histological cell type, radiation dose, and use of chemotherapy were not significantly associated with survival.
引用
收藏
页码:558 / 566
页数:9
相关论文
共 50 条
[1]  
[Anonymous], 1982, CANCER, V49, P2112
[2]   RADIATION-THERAPY IN THE MANAGEMENT OF PRIMARY MALIGNANT-LYMPHOMA OF THE BRAIN [J].
BERRY, MP ;
SIMPSON, WJ .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1981, 7 (01) :55-59
[3]   MANAGEMENT OF PRIMARY CEREBRAL LYMPHOMA WITH INITIAL CHEMOTHERAPY - PRELIMINARY-RESULTS AND COMPARISON WITH PATIENTS TREATED WITH RADIOTHERAPY ALONE [J].
BRADA, M ;
DEARNALEY, D ;
HORWICH, A ;
BLOOM, HJG .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1990, 18 (04) :787-792
[4]  
CHAMBERLAIN MC, 1992, J NEURO-ONCOL, V14, P271
[5]  
COX DR, 1972, J R STAT SOC B, V34, P187
[6]  
DEANGELIS L M, 1992, Neurology, V42, P389
[7]   PRIMARY CNS LYMPHOMA - COMBINED TREATMENT WITH CHEMOTHERAPY AND RADIOTHERAPY [J].
DEANGELIS, LM ;
YAHALOM, J ;
HEINEMANN, MH ;
CIRRINCIONE, C ;
THALER, HT ;
KROL, G .
NEUROLOGY, 1990, 40 (01) :80-86
[8]   PRIMARY CENTRAL-NERVOUS-SYSTEM LYMPHOMA - A NEW CLINICAL CHALLENGE [J].
DEANGELIS, LM .
NEUROLOGY, 1991, 41 (05) :619-621
[9]   EFFECT OF AGE ON THERAPEUTIC OUTCOME IN ADVANCED DIFFUSE HISTIOCYTIC LYMPHOMA - THE SOUTHWEST-ONCOLOGY-GROUP EXPERIENCE [J].
DIXON, DO ;
NEILAN, B ;
JONES, SE ;
LIPSCHITZ, DA ;
MILLER, TP ;
GROZEA, PN ;
WILSON, HE .
JOURNAL OF CLINICAL ONCOLOGY, 1986, 4 (03) :295-305
[10]  
EBY NL, 1988, CANCER, V62, P2461, DOI 10.1002/1097-0142(19881201)62:11<2461::AID-CNCR2820621135>3.0.CO